Successful self-infusion of activated prothrombin complex concentrate for prophylaxis in a child with a factor VIII inhibitor

American Journal of Hematology

Volumn 82, Issue 2, 2007, Pages 145-149

  Ohga, Shouichi ^a   Nomura, Akihiko ^a   Takada, Hidetoshi ^a   Suga, Naohiro ^a   Hara, Toshiro ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

FEIBA; Inhibitor; Prophylaxis; PROPLEX; rFVIIa

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; CROSSEIGHT M; PROPLEX ST; RECOMBINANT BLOOD CLOTTING FACTOR 7A; UNCLASSIFIED DRUG;

ADOLESCENT; ANAMNESIS; ARTICLE; BRAIN HEMORRHAGE; CASE REPORT; DISEASE COURSE; DRUG SELF ADMINISTRATION; HEMARTHROSIS; HEMOPHILIA A; HUMAN; INFUSION PUMP; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT DISEASE; TREATMENT OUTCOME;

ADOLESCENT; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION FACTORS; HEMOPHILIA A; HEMORRHAGE; HUMANS; JAPAN; JOINT DISEASES; MALE; SELF ADMINISTRATION; THROMBOSIS;

EID: 33846521185     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20751     Document Type: Article

References (18)

1. Ingerslev J. Hemophilia. Strategies for the treatment of inhibitor patients. Haematologica 2000;85(Suppl. 10):15-20.
2. Luu H, Ewenstein B. FEIBA safety profile in multiple modes of clinical and home-therapy application. Haemophilia 2004; 10(Suppl. 2):10-16.
3. Hilgartner M, Aledort L, Andes A, Gill J. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group. Transfusion 1990;30:626-630.
4. Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Thromb Haemost 1997:77:1113-1119.
5. Sjamsoedin LJ, Heijnen L, Mauser-Bunschoten EP, et al. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. New Engl J Med 1981;305:717-721.
6. Kreuz W, Escuriola-Ettinghausen C, Mentzer D, Martinez I, Becker S, Stoll H. Factor VIII inhibitor bypass activity (FEIBA) for prophylaxis during immune tolerance induction (ITI) in patients with high-responding inhibitors. Blood 2000;96:266a.
7. Leissinger CA. Prevention of bleeds in hemophilia patients with inhibitors: Emerging data and clinical direction. Am J Hematol 2004;77:187-193.
8. Hilgartner MW, Makipernaa A, Dimichele DM. Long-term FEIBA prophylaxis does not prevent progression of existing joint disease. Haemophilia 2003;9:261-268.
9. Escuriola-Ettingshausen C, Martinez Saguer I, Funk MB, et al. Long-term prophylaxis with FEIBA in patients with high-responding inhibitors. J Thromb Haemost 2003;1(Suppl. 1): Abst. 1628.
10. Ewing N. Anamnestic responses in hemophilia patients with inhibitors on continuous prophylaxis with factor VIII inhibitor bypassing activity, vapor-heated (FEIBA VH). J Thromb Haemost 2005;3(Suppl. 1): Abst. 2036.
11. Leissinger CA, Becton DL, Ewing NP, Valentino LA. Prophylaxis with factor VlII inhibitor bypassing activity, vapor heated (FEIBA VH) decreases bleeding frequency and maintains or improves joint status. J Thromb Haemost 2005;3(Suppl. 1): Abst. 1436.
12. Valentino LA, Salit MG. Prophylactic use of FEIBA in children with hemophilia complicated by high-titered inhibitors. Blood 2002;100:102b.
13. Dimichele D, Rivard G, Hay C, Antunes S. Inhibitors in haemophilia: Clinical aspects. Haemophilia 2004;10(Suppl. 4):140-145. 14. Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia 2002;8:83-90.
14. Cooper HA, Jones CP, Campion E, Roberts HR, Hedner U. Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures. Haemophilia 2001;7:517-522.
15. Shirahata A, Kamiya T, Takamatsu J, et al. Clinical trial to investigate the pharmacokinetics, pharmacodynamics, safety, and efficacy of recombinant factor VIIa in Japanese patients with hemophilia with inhibitors. Int J Hematol 2001;73:517-525.
16. Hayashi T, Tanaka I, Shima M, et al. Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life-threatening massive bleeding in a patient with haemophilia A and a high responding inhibitor. Haemophilia 2004; 10:397-400.
17. Schneiderman J, Nugent DJ, Young G. Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors. Haemophilia 2004;10:347-351.
18. Key NS, Christie B, Henderson N, Nelsestuen GL. Possible synergy between recombinant factor VIIa and prothrombin complex concentrate in hemophilia therapy. Thromb Haemost 2002;88:60-65.